The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Davydovskaya M.V.

Research and Practical Centre for Clinical Investigations and Evaluation of Medical Technologies, Moscow Health Department, Moscow, Russia

Khachanova N.V.

Burdenko Neurosurgical Institute, Moscow, Russia

Evdoshenko E.P.

Sankt-Peterburgskoe GBUZ "Gorodskaia klinicheskaia bol'nitsa #31", Sankt-Peterburgskiĭ gorodskoĭ Tsentr rasseiannogo skleroza i autoimmunnykh zabolevaniĭ, Sankt-Peterburg

Pronin I.N.

NII neĭrokhirurgii im. akad. N.N. Burdenko RAMN, Moskva

Boĭko A.N.

KGBUZ "Krasnoiarskiĭ kraevoĭ Tsentr po profilaktike i bor'be so SPID i infektsionnymi zabolevaniiami"

Zakharova M.N.

Nauchnyĭ tsentr nevrologii RAMN, Moskva

Alifirova V.M.

Sibirskiĭ gosudarstvennyĭ meditsinskiĭ universitet, Tomsk, Russia

Turova E.A.

Siberian Regional Hospital №1, Yekaterinburg, Russia

Malkova N.A.

Novosibirskiĭ okruzhnoĭ tsentr rasseiannogo skleroza

Sivertseva S.A.

Tiumenskiĭ oblastnoĭ tsentr rasseiannogo skleroza

Tsukurova L.A.

Kraevaia klinicheskaia bol'nitsa #1 im. prof. S.V. Ochapovskogo, Krasnodar

Skoromets A.A.

Sankt-Peterburgskiĭ gosudarstvennyĭ meditsinskiĭ institut im. akad. I.P. Pavlova

Solodun I.Yu.

Center of Coordination and Clinical Examination of Medical Drugs, Moscow Department of Public Health, Moscow, Russia

Recommendations on the algorithms for drug choice and risk management plan in the treatment of patients with remitting multiple sclerosis with natalizumab

Authors:

Davydovskaya M.V., Khachanova N.V., Evdoshenko E.P., Pronin I.N., Boĭko A.N., Zakharova M.N., Alifirova V.M., Turova E.A., Malkova N.A., Sivertseva S.A., Tsukurova L.A., Skoromets A.A., Solodun I.Yu.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2016;116(10‑2): 79‑97

DOI: 10.17116/jnevro201611610279-97

Read: 6955 times

Contact the author
Table of contents

RECOMMENDATIONS ON THE ALGORITHMS FOR DRUG CHOICE AND RISK MANAGEMENT PLAN IN THE TREATMENT OF PATIENTS WITH REMITTING MULTIPLE SCLEROSIS WITH NATALIZUMAB
RECOMMENDATIONS ON THE ALGORITHMS FOR DRUG CHOICE AND RISK MANAGEMENT PLAN IN THE TREATMENT OF PATIENTS WITH REMITTING MULTIPLE SCLEROSIS WITH NATALIZUMAB

To cite this article:

Davydovskaya MV, Khachanova NV, Evdoshenko EP, et al. Recommendations on the algorithms for drug choice and risk management plan in the treatment of patients with remitting multiple sclerosis with natalizumab. S.S. Korsakov Journal of Neurology and Psychiatry. 2016;116(10‑2):79‑97. (In Russ.)
https://doi.org/10.17116/jnevro201611610279-97

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски (S.S. Korsakov Journal of Neurology and Psychiatry (special issues))
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Abstract:

Authors:

Davydovskaya M.V.

Research and Practical Centre for Clinical Investigations and Evaluation of Medical Technologies, Moscow Health Department, Moscow, Russia

Khachanova N.V.

Burdenko Neurosurgical Institute, Moscow, Russia

Evdoshenko E.P.

Sankt-Peterburgskoe GBUZ "Gorodskaia klinicheskaia bol'nitsa #31", Sankt-Peterburgskiĭ gorodskoĭ Tsentr rasseiannogo skleroza i autoimmunnykh zabolevaniĭ, Sankt-Peterburg

Pronin I.N.

NII neĭrokhirurgii im. akad. N.N. Burdenko RAMN, Moskva

Boĭko A.N.

KGBUZ "Krasnoiarskiĭ kraevoĭ Tsentr po profilaktike i bor'be so SPID i infektsionnymi zabolevaniiami"

Zakharova M.N.

Nauchnyĭ tsentr nevrologii RAMN, Moskva

Alifirova V.M.

Sibirskiĭ gosudarstvennyĭ meditsinskiĭ universitet, Tomsk, Russia

Turova E.A.

Siberian Regional Hospital №1, Yekaterinburg, Russia

Malkova N.A.

Novosibirskiĭ okruzhnoĭ tsentr rasseiannogo skleroza

Sivertseva S.A.

Tiumenskiĭ oblastnoĭ tsentr rasseiannogo skleroza

Tsukurova L.A.

Kraevaia klinicheskaia bol'nitsa #1 im. prof. S.V. Ochapovskogo, Krasnodar

Skoromets A.A.

Sankt-Peterburgskiĭ gosudarstvennyĭ meditsinskiĭ institut im. akad. I.P. Pavlova

Solodun I.Yu.

Center of Coordination and Clinical Examination of Medical Drugs, Moscow Department of Public Health, Moscow, Russia

Close metadata

References:

  1. The Ministry of Health of Russian Federation 22.04.15. Instructions for use of the drug for medical use of tysabri. (In Russ.).
  2. Alifirova VM, Bakhtiyarova KZ, Belova AN, Bisaga GN, Boyko AN, Vlasov YV, Volkova LI, Gavrilenko AA, Guekht AB, Gusev EI, Davydovskaya MV, Evdoshenko EP, Zakharova MN, Kotov SV, Lapin SV, Malkova NA, Petrov AM, Popova NF, Sivertseva SA, Skoromets AG, Stolyarov ID, Streknev AG, Totolyan NA, Schmidt TE, Khabirov FA, Khachanova NV, Yakupov EZ. Recommendation for use of new drugs (tysabri, gylenia, movectro) for pathogenic multiple sclerosis treatment. M.: ROOI «Zdorovie cheloveka»; 2011. (In Russ.).
  3. Boyko AN, Boyko OV, Gusev EI. The choice of the optimal drug for pathogenic treatment of multiple sclerosis: a current state of the problem. Zhurnal nevrologii I psikhiatrii imeni S.S. Korsakova. 2014;114:10(2):77-91. (In Russ.).
  4. Boyko AN, Evdoshenko EP, Vorobyeva OV, You X, Pukaite V. Prospective, open, non-randomized clinical trial on the safety and efficacy of natalizumab (tysabri) in the Russian population of patients with relapsing-remitting multiple sclerosis. Zhurnal nevrologii I psikhiatrii imeni S.S. Korsakova. 2015;115:8(2):25-35. (In Russ.).
  5. Davydovskaya MV. Risk management plan for natalizumab therapy. Zhurnal nevrologii I psikhiatrii imeni S.S. Korsakova. 2011;2:105-109. (In Russ.).
  6. The criteria of ineffectiveness and for stopping first-line DMD therapy and switching on second-line. Zhurnal nevrologii I psikhiatrii imeni S.S. Korsakova. 2015;115:8(2):44. (In Russ.). doi: 10.17116/nevro20151158244
  7. Popova EV, Brylev LV, Davydovskaya MV. Natalizumab in the treatment of patients with relapsing-remitting multiple sclerosis: the preliminary results of the observational program «Sovet». Zhurnal nevrologii I psikhiatrii imeni S.S. Korsakova. 2013;113:2(2):79-82. (In Russ.).
  8. Yakushina TI, Eliseev YuV, Kotov SV. A rare case of ineffective therapy with natalizumab (tisabri) in a female patient with multiple sclerosis and neutralizing antibodies to the drug. Zhurnal nevrologii I psikhiatrii imeni S.S. Korsakova. 2013;113:2(2):83-86. (In Russ.).
  9. Aksamit A. Treatment of non-AIDS progressive multifocal leukoencephalopathy with cytosine arabinoside. J Neurovirol. 2001;7(4):386-390. doi: 10.1080/13550280152537292
  10. Albrecht H, Hoffmann C, Degen O et al. Highly active antiretroviral therapy significantly improves the prognosis of patients with HIV-associated progressive multifocal leukoencephalopathy. AIDS. 1998;12(10):1149-1154. doi: 10.1097/00002030-199810000-00006
  11. Antinori A, Cingolani A, Lorenzini P et al. Clinical Epidemiology and Survival of Progressive Multifocal Leukoencephalopathy in the Era of Highly Active Antiretroviral Therapy: Data from the Italian Registry Investigative Neuro AIDS (IRINA). J Neurovirol. 2003;9(1):47-53. doi: 10.1080/13550280390195388
  12. Åstrom K, Mancall E, Richardson E. Progressive multifocal leukoencephalopathy. Brain. 1958;81(1):93-111. doi: 10.1093/brain/81.1.93
  13. Belachew S, Butzkueven H, Kappos L. et al. Natalizumab Observation program: associations of baseline disease activity and treatment history with post baseline relapses in MS patients treated with natalizumab. Presented at ECTRIMS. 2010. P494. Available at: http://registration.akm.ch/einsicht.php?XNABSTRACT_ID=116871&XNSPRACHE_ID=1&XNKONGRESS_ID=126&XNMASKEN_ID=900
  14. Berenguer J, Miralles P, Arrizabalaga J et al. Clinical Course and Prognostic Factors of Progressive Multifocal Leukoencephalopathy in Patients Treated with Highly Active Antiretroviral Therapy. Clinical Infectious Diseases. 2003;36(8):1047-1052. doi: 10.1086/374048
  15. Berger J, Aksamit A, Clifford D et al. PML diagnostic criteria: Consensus statement from the AAN Neuroinfectious Disease Section. Neurology. 2013;80(15):1430-1438. doi: 10.1212/wnl.0b013e31828c2fa1
  16. Berger J, Pall L, Lanska D, Whiteman M. Progressive Multifocal Leukoencephalopathy in Patients with HIV Infection. J Neurovirol. 1998;4(1):59-68. doi: 10.3109/13550289809113482
  17. Biogen Idec Inc., Elan Pharmaceuticals I. TYSABRI Prescribing Information, US Food and Drug Administration. 2014.
  18. Bozic C, Subramanyam M, Richman S, Plavina T, Zhang A, Ticho B. Anti-JC virus (JCV) antibody prevalence in the JCV Epidemiology in MS (JEMS) trial. Eur J Neurol. 2013;21(2):299-304. doi: 10.1111/ene.12304
  19. Bozic C, LaGuette J, Panzara M, Sandrock A. Natalizumab and central nervous system lymphoma: No clear association. Annals of Neurology. 2009;66(3):261-262. doi: 10.1002/ana.21835
  20. Chan PY, Aruffo A. VLA-4 integrin mediates lymphocytes migration on the inducible endothelial cell ligand VCAM-1. J Biol Chem. 1993;268:25655-24664. Available at: http://www.jbc.org/content/268/33/24655.full.pdf
  21. Cinque P, Scarpellini P, Vago L, Linde A, Lazzarin A. Diagnosis of central nervous system complications in HIV-infected patients. AIDS. 1997;11(1):1-17. doi: 10.1097/00002030-199701000-00003
  22. Clifford D, DeLuca A, Simpson D, Arendt G, Giovannoni G, Nath A. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. The Lancet Neurology. 2010;9(4):438-446. doi: 10.1016/s1474-4422(10)70028-4
  23. Clifford D, Yiannoutsos C, Glicksman M et al. HAART improves prognosis in HIV-associated progressive multifocal leukoencephalopathy. Neurology. 1999;52(3):623-623. doi: 10.1212/wnl.52.3.623
  24. Coyle P, Foley J, Fox E, Jeffery D, Munschauer F, Tornatore C. Best practice recommendations for the selection and management of patients with multiple sclerosis receiving natalizumab therapy. Multiple Sclerosis. 2009;15(4 suppl):26-36. doi: 10.1177/1352458509347131
  25. Coyle P, Jeffery D. Clinical efficacy and benefit of natalizumab. Multiple Sclerosis. 2009;15(4 suppl):7-15. doi: 10.1177/1352458509347129
  26. Cristiano LM, Bozic C, Bloomgren G, Kooijmans-Coutinho M. Preliminary Evaluation of Prospective Pregnancy Outcomes from the TYSABRI (natalizumab) Pregnancy Registry. Presented at ECTRIMS. 2010;197-352; 840. Available at: http://registration.akm.ch/einsicht.php?XNABSTRACT_ID=116749&XNSPRACHE_ID=1&XNKONGRESS_ID=126&XNMASKEN_ID=900
  27. Crowder C, Gyure K, Drachenberg C et al. Successful Outcome of Progressive Multifocal Leukoencephalopathy in a Renal Transplant Patient. Am J Transplant. 2005;5(5):1151-1158. doi: 10.1111/j.1600-6143.2005.00800.x
  28. Egli A, Infanti L, Dumoulin A et al. Prevalence of Polyomavirus BK and JC Infection and Replication in 400 Healthy Blood Donors. The Journal of Infectious Diseases. 2009;199(6):837-846. doi: 10.1086/597126
  29. Elston J, Thaker H. Immune reconstitution inflammatory syndrome. International Journal of STD & AIDS. 2009;20(4):221-224. doi: 10.1258/ijsa.2008.008449
  30. Eng P, Turnbull B, Cook S, Davidson J, Kurth T, Seeger J. Characteristics and antecedents of progressive multifocal leukoencephalopathy in an insured population. Neurology. 2006;67(5):884-886. doi: 10.1212/01.wnl.0000233918.21986.9c
  31. European Medicines Agency. TYSABRY Product Information. 2009.
  32. Fernández O, García-Merino J, Arroyo R et al. Spanish consensus on the use of natalizumab (Tysabri)-2013. Neurología (English Edition). 2015;30(5):302-314. doi:10.1016/j.nrleng.2013.10.023
  33. Fox R, Cree B, De Seze J et al. MS disease activity in RESTORE: A randomized 24-week natalizumab treatment interruption study. Neurology. 2014;82(17):1491-1498. doi: 10.1212/wnl.0000000000000355
  34. Gasnault, Pascale Kousignian, Mufid J. Cidofovir in AIDS-associated progressive multifocal leukoencephalopathy: A monocenter observational study with clinical and JC virus load monitoring. J Neurovirol. 2001;7(4):375-381. doi: 10.1080/13550280152537274
  35. Geschwind D, Skolasky RI, Roya WSM. The relative contributions of HAART and alpha-interferon for therapy of progressive multifocal leukoencephalopathy in AIDS. J Neurovirol. 2001;7(4):353-357. doi: 10.1080/13550280152537238
  36. Ghezzi A, Grimaldi L, Marrosu M et al. Natalizumab therapy of multiple sclerosis: recommendations of the Multiple Sclerosis Study Group — Italian Neurological Society. Neurological Sciences. 2011;32(2):351-358. doi: 10.1007/s10072-010-0469-0
  37. Gold R, Jawad A, Miller D et al. Expert opinion: Guidelines for the use of natalizumab in multiple sclerosis patients previously treated with immunomodulating therapies. Journal of Neuroimmunology. 2007;187(1-2):156-158. doi: 10.1016/j.jneuroim.2007.04.006
  38. Gorelik L, Lerner M, Bixler S et al. Anti-JC virus antibodies: Implications for PML Risk Stratification. Annals of Neurology. 2010;68(3):295-303. doi: 10.1002/ana.22128
  39. Gunnarsson M, Malmeström C, Axelsson M et al. Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab. Annals of Neurology. 2010;69(1):83-89. doi: 10.1002/ana.22247
  40. Hall C, Dafni U, Simpson D et al. Failure of Cytarabine in Progressive Multifocal Leukoencephalopathy Associated with Human Immunodeficiency Virus Infection. New England Journal of Medicine. 1998;338(19):1345-1351. doi: 10.1056/nejm199805073381903
  41. Havrdova E, Galetta S, Hutchinson M et al. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. The Lancet Neurology. 2009;8(3):254-260. doi: 10.1016/s1474-4422(09)70021-3
  42. Hoepner R, Havla J, Eienbroker C et al. Predictors for multiple sclerosis relapses after switching from natalizumab to fingolimod. Multiple Sclerosis Journal. 2014;20(13):1714-1720. doi: 10.1177/1352458514533398
  43. Honce J, Nagae L, Nyberg E. Neuroimaging of Natalizumab Complications in Multiple Sclerosis: PML and Other Associated Entities. Multiple Sclerosis International. 2015;2015:1-14. doi: 10.1155/2015/809252
  44. Kappos L, Bates D, Edan G et al. Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. The Lancet Neurology. 2011;10(8):745-758. doi: 10.1016/s1474-4422(11)70149-1
  45. Kean J, Rao S, Wang M, Garcea R. Seroepidemiology of Human Polyomaviruses. PLoS Pathog. 2009;5(3):1000363. doi: 10.1371/journal.ppat.1000363
  46. Khatri B, Man S, Giovannoni G et al. Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function. Neurology. 2009;72(5):402-409. doi: 10.1212/01.wnl.0000341766.59028.9d
  47. Kleinschmidt-DeMasters B, Tyler K. Progressive Multifocal Leukoencephalopathy Complicating Treatment with Natalizumab and Interferon Beta-1a for Multiple Sclerosis. New England Journal of Medicine. 2005;353(4):369-374. doi: 10.1056/nejmoa051782
  48. Knowles W, Pipkin P, Andrews N et al. Population-based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40. J Med Virol. 2003;71(1):115-123. doi: 10.1002/jmv.10450
  49. Killestein J, Vennegoor A, Strijbis E et al. Natalizumab drug holiday in multiple sclerosis: Poorly Tolerated. Annals of Neurology. 2010;68(3):392-395. doi: 10.1002/ana.22074
  50. Koralnik I. New insights into progressive multifocal leukoencephalopathy. Current Opinion in Neurology. 2004;17(3):365-370. doi: 10.1097/00019052-200406000-00019
  51. Langer-Gould A, Atlas S, Green A, Bollen A, Pelletier D. Progressive Multifocal Leukoencephalopathy in a Patient Treated with Natalizumab. New England Journal of Medicine. 2005;353(4):375-381. doi: 10.1056/nejmoa051847
  52. Lee S, Benveniste E. Adhesion molecule expression and regulation on cells of the central nervous system. Journal of Neuroimmunology. 1999;98(2):77-88. doi: 10.1016/s0165-5728(99)00084-3
  53. Mader I, Herrlinger U, Klose U, Schmidt F, Kuker W. Progressive multifocal leukoencephalopathy: analysis of lesion development with diffusion-weighted MRI. Neuroradiology. 2003;45(10):717-721. doi: 10.1007/s00234-003-0966-4
  54. Maginnis M, Stroh L, Gee G et al. Progressive Multifocal Leukoencephalopathy-Associated Mutations in the JC Polyomavirus Capsid Disrupt Lactoseries Tetrasaccharide c Binding. mBio. 2013;4(3):e00247-13-e00247-13. doi: 10.1128/mbio.00247-13
  55. Marra C, Rajicic N, Barker D et al. A pilot study of cidofovir for progressive multifocal leukoencephalopathy in AIDS. AIDS. 2002;16(13):1791-1797. doi: 10.1097/00002030-200209060-00012
  56. Monaco MC, Shin J., Major EO. JC virus infection in cells from lymphoid tissue. Dev Biol Stand. 1998;94:115-122. MID:9776232
  57. Mullen J, Vartanian T, Atkins M. Melanoma Complicating Treatment with Natalizumab for Multiple Sclerosis. New England Journal of Medicine. 2008;358(6):647-648. doi: 10.1056/nejmc0706103
  58. Munschauer F, Benedict R, Granger C, Niewczyk P. Introduction to Best practice recommendations for the selection and management of patients with MS on natalizumab. Multiple Sclerosis. 2009;15(4 suppl):1-6. doi: 10.1177/1352458509347127
  59. O’Connor P, Goodman A, Kappos L et al. Long-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS Study. Neurology. 2014;83(8):773-773. doi: 10.1212/wnl.0000000000000766
  60. O'Leary S, Beavin J, Bishop C, Capolino L, Greinel E, Hudson E. Practical Guidelines for Administering Natalizumab: A Nursing Perspective. International Journal of MS Care. 2007;9(1):1-8. doi: 10.7224/1537-2073-9.1.1
  61. Oturai A, Koch-Henriksen N, Petersen T, Jensen P, Sellebjerg F, Sorensen P. Efficacy of natalizumab in multiple sclerosis patients with high disease activity: a Danish nationwide study. European Journal of Neurology. 2009;16(3):420-423. doi: 10.1111/j.1468-1331.2008.02517.x
  62. Outteryck O, Ongagna J, Zéphir H et al. Demographic and clinic characteristics of French patients treated with natalizumab in clinical practice. Journal of Neurology. 2009;257(2):207-211. doi: 10.1007/s00415-009-5294-0
  63. Padgett B, Walker D. Prevalence of Antibodies in Human Sera against JC Virus, an Isolate from a Case of Progressive Multifocal Leukoencephalopathy. Journal of Infectious Diseases. 1973;127(4):467-470. doi: 10.1093/infdis/127.4.467
  64. Panzara MA, Bozik C, Sandrock AW et al. More on melanoma with transdifferenti tion. New England Journal of Medicine. 2008;359(1):99-100. doi: 10.1056/NEJMc086089
  65. Padgett B, Zurhein G, Walker D, Eckroade R, Dessel B. Cultivation of papova-like virus from human brain with progressive multifocal leucoencephalopathy. The Lancet. 1971;297(7712):1257-1260. doi: 10.1016/s0140-6736(71)91777-6
  66. Plavina T, Subramanyam M, Bloomgren G et al. Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy. Annals of Neurology. 2014;76(6):802-812. doi: 10.1002/ana.24286.
  67. Polman C, Reingold S, Banwell B et al. Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria. Annals of Neurology. 2011;69(2):292-302. doi: 10.1002/ana.22366
  68. Polman C, O'Connor P, Havrdova E et al. A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis. New England Journal of Medicine. 2006;354(9):899-910. doi: 10.1056/nejmoa044397
  69. Portegies P, Solod L, Cinque P et al. Guidelines for the diagnosis and management of neurological complications of HIV infection. Eur J Neurol. 2004;11(5):297-304. doi:10.1111/j.1468-1331.2004.00856.x
  70. Putzki N, Yaldizli O, Mäurer M et al. Efficacy of natalizumab in second line therapy of relapsing–remitting multiple sclerosis: results from a multi-center study in German speaking countries. European Journal of Neurology. 2010;17(1):31-37. doi: 10.1111/j.1468-1331.2009.02728.x
  71. Ray U, Cinque P, Gerevini S et al. JC polyomavirus mutants escape antibody-mediated neutralization. Science Translational Medicine. 2015;7(306):306ra151-306ra151. doi: 10.1126/scitranslmed.aab1720
  72. Rinaldi F, Calabrese M, Seppi D, Puthenparampil M, Perini P, Gallo P. Natalizumab strongly suppresses cortical pathology in relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal. 2012;18(12):1760-1767. doi: 10.1177/1352458512447704
  73. Rudick R, O'Connor P, Polman C et al. Assessment of JC virus DNA in blood and urine from natalizumab-treated patients. Annals of Neurology. 2010;68(3):304-310. doi: 10.1002/ana.22107
  74. Rudick R, Sandrock A. Natalizumab: α4-integrin antagonist selective adhesion molecule inhibitors for MS. Expert Review of Neurotherapeutics. 2004;4(4):571-580. doi: 10.1586/14737175.4.4.571
  75. Rudick R, Stuart W, Calabresi P et al. Natalizumab plus Interferon Beta-1a for Relapsing Multiple Sclerosis. New England Journal of Medicine. 2006;354(9):911-923. doi: 10.1056/nejmoa044396
  76. Safak M, Khalili K. An overview: Human Polyomavirus JC Virus and its Associated Disorders. J Neurovirol. 2003;9(1):3-9. doi: 10.1080/13550280390195360
  77. Schweikert A, Kremer M, Ringel F et al. Primary central nervous system lymphoma in a patient treated with natalizumab. Annals of Neurology. 2009;66(3):403-406. doi: 10.1002/ana.21782
  78. Selewski D, Shah G, Segal B, Rajdev P, Mukherji S. Natalizumab (Tysabri). American Journal of Neuroradiology. 2010;31(9):1588-1590. doi: 10.3174/ajnr.a2226
  79. Shitrit D, Lev N, Bar-Gil-Shitrit A, Kramer M. Progressive multifocal leukoencephalopathy in transplant recipients. Transplant International. 2004;17(11):658-665. doi: 10.1007/s00147-004-0779-3
  80. Simon JH, Li D, Traboulsee A et al. Standardized MR Imaging Protocol for Multiple Sclerosis: Consortium of MS Centers Consensus Guidelines. AJNR Am J Neuroradiol. 2006;27(2):455-461.
  81. Sorensen P, Bertolotto A, Edan G et al. Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. Multiple Sclerosis Journal. 2012;18(2):143-152. doi: 10.1177/1352458511435105
  82. Svenningsson A, Falk E, Celius E et al. Natalizumab Treatment Reduces Fatigue in Multiple Sclerosis. Results from the TYNERGY Trial; A Study in the Real Life Setting. PLoS ONE. 2013;8(3):58643. doi: 10.1371/journal.pone.0058643
  83. Talan J. Haart Therapy for HIV-AIDS Prompts PML and Immune Reconstitution Inflammatory Syndrome. Neurology Today. 2009;9(4):8-9. doi: 10.1097/01.nt.0000346475.29853.6b
  84. Tan K, Roda R, Ostrow L, McArthur J, Nath A. PML-IRIS in patients with HIV infection: Clinical manifestations and treatment with steroids. Neurology. 2009;72(17):1458-1464. doi: 10.1212/01.wnl.0000343510.08643.74
  85. Tornatore C, Clifford D. Clinical vigilance for progressive multifocal leukoencephalopathy in the context of natalizumab use. Multiple Sclerosis. 2009;15(4 suppl):16-25. doi: 10.1177/1352458509347130
  86. Totaro R.,Lugaresi A., Bellantonio P et al Natalizumab treatment in multiple sclerosis patients: a multicenter experience in clinical practice in Italy. Int j Immunopathol Pharmacol. 2014;27:147-154. PMID: 25004826
  87. Tremlett H, Seemuller S, Zhao Y, Yoshida E, Oger J, Petkau J. Liver test abnormalities in multiple sclerosis: Findings from placebo-treated patients. Neurology. 2006;67(7):1291-1293. doi: 10.1212/01.wnl.0000238515.27055.62
  88. Van Assche G, Van Ranst M, Sciot R et al. Progressive Multifocal Leukoencephalopathy after Natalizumab Therapy for Crohn's Disease. New England Journal of Medicine. 2005;353(4):362-368. doi: 10.1056/nejmoa051586
  89. Vermersch P, Foley J, Gold R. et al. Overview of clinical outcomes in cases of natalizumab-Associated progressive multifocal leukoencephalopathy. Presented at ECTRIMS. 2010;112. Avalable at: http://registration.akm.ch/einsicht.php?XNABSTRACT_ID=116789&XNSPRACHE_ID=1&XNKONGRESS_ID=126&XNMASKEN_ID=900
  90. Voloshyna N, Havrdová E, Hutchinson M et al. Natalizumab improves ambulation in relapsing — remitting multiple sclerosis: results from the prospective TIMER study and a retrospective analysis of AFFIRM. Eur J Neurol. 2014;22(3):570-577. doi: 10.1111/ene.12618
  91. von Andrian U, Engelhardt B. α 4 Integrins as Therapeutic Targets in Autoimmune Disease. New England Journal of Medicine. 2003;348(1):68-72. doi: 10.1056/nejme020157
  92. Wattjes M, Vennegoor A, Steenwijk M et al. MRI pattern in asymptomatic natalizumab-associated PML. Journal of Neurology, Neurosurgery & Psychiatry. 2014;86(7):793-798. doi: 10.1136/jnnp-2014-308630
  93. Wattjes M, Rovira À, Miller D et al. Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis — establishing disease prognosis and monitoring patients. Nature Reviews Neurology. 2015;11(10):597-606. doi: 10.1038/nrneurol.2015.157
  94. Wenning W, Haghikia A, Laubenberger J et al. Treatment of Progressive Multifocal Leukoencephalopathy Associated with Natalizumab. New England Journal of Medicine. 2009;361(11):1075-1080. doi: 10.1056/nejmoa0810257
  95. Whiteman M, Post M, Berger J, Tate L, Bell M, Limonte L. Progressive multifocal leukoencephalopathy in 47 HIV-seropositive patients: neuroimaging with clinical and pathologic correlation. Radiology. 1993;187(1):233-240. doi: 10.1148/radiology.187.1.8451420
  96. Yousry T, Pelletier D, Cadavid D et al. Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy. Annals of Neurology. 2012;72(5):779-787. doi: 10.1002/ana.23676
  97. Yousry T, Major E, Ryschkewitsch C et al. Evaluation of Patients Treated with Natalizumab for Progressive Multifocal Leukoencephalopathy. New England Journal of Medicine. 2006;354(9):924-933. doi: 10.1056/nejmoa054693
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.